Zealand Pharma

Director's Dealing • Apr 2, 2013

Report of insider transactions No. 2/2013

REPLACEMENT: WORDING IN LEFT-HAND COLUMN OF TABLE AMENDED

Zealand Pharma A/S Announcement of transactions in the company's shares and related securities by executives and their related parties

Copenhagen, 18 March 2013 – Pursuant to the Danish Securities Trading Act, section 28a, Zealand Pharma A/S ("Zealand") shall announce transactions in the company's shares and related securities by executives and persons/companies closely related to them.

Name:	David H. Solomon
Reason:	President and Chief Executive Officer
Issuer:	Zealand Pharma A/S
Type	Shares
ISIN code:	DK0060257814
Transaction:	Purchase
Trading date:	14 March 2013
Market:	NASDAQ OMX København A/S
Amount:	20,600
Price:	DKK 90.9323
Market value:	DKK 1,873,206.20

In this regard, Zealand announces the following transaction:

Hereafter, David H. Solomon owns 20,600 shares and 387,150 warrants in Zealand.

#

For further information, please contact:

David Solomon, President and Chief Executive Officer, Tel: +45 2220 6300

Hanne Leth Hillman, Vice President and Head of IR & Corporate Communication Tel: +45 5060 3689, email: hlh@zealandpharma.com

Zealand Pharma A/S

Announcement of transactions in the company's shares and related securities by executives and their related parties

About Zealand

Zealand Pharma A/S ("Zealand") (NASDAQ OMX Copenhagen: ZEAL) is a biotechnology company based in Copenhagen, Denmark. Zealand specializes in the discovery, optimization and development of novel peptide drugs and has a broad and mature pipeline of drug candidates identified through its own drug discovery activities. The company's focus lies in the field of diabetes/metabolic diseases, and its lead drug invention is lixisenatide, a once-daily GLP-1 agonist, which is licensed to Sanofi for the treatment of Type 2 diabetes. Lixisenatide is approved in Europe (February 2013) under the name of Lyxumia®, and under regulatory review in a large number of other countries globally, including in the US (NDA filed in Dec 2012) and Japan (NDA filed in June 2013).

Zealand has a partnering strategy for the development and commercialization of its products and in addition to the collaboration with Sanofi in Type 2 diabetes, the company has partnerships with Boehringer Ingelheim in diabetes/obesity, Helsinn Healthcare in chemotherapy induced diarrhea and AbbVie in acute kidney injury. For further information: www.zealandpharma.com